REVOLUTIONIZING

Respiratory Disease

TREATMENTS

Spirovant is a gene therapy company developing treatments and cures for respiratory diseases including cystic fibrosis.

SCIENCE & TECHNOLOGY

Spirovant designs novel therapies for cystic fibrosis and other respiratory diseases.

The company’s current gene therapy technologies are designed to overcome the historical barriers that have prevented effective genetic treatments for cystic fibrosis.

Spirovant’s lead program is in development for cystic fibrosis and includes our proprietary Adeno-Associated Virus (AAV) platform.

 

AAV + Augmenter Platform

Our AAV + Augmenter platform consists of an optimized transgene payload, a novel AAV capsid, and an augmenter, which collectively drive the high expression of the functional cystic fibrosis transmembrane conductance regulator (CFTR) protein in human airway epithelia.

ABOUT US

AN AWARD WINNING TEAM

TREATING Respiratory diseases.

Chief Executive Officer

Joan Lau, PhD, MBA

Chief Executive Officer

Joan Lau, PhD, MBA

Joan Lau is Chief Executive Officer of Spirovant, responsible for the strategic direction and growth of the gene therapy company. She delivers more than 20 years of biopharma leadership experience, including as CEO for several venture-capital-backed biotech companies. Dr. Lau co-founded Spirovant (then called Talee Bio), envisioning the potential for advanced gene therapy to treat cystic fibrosis and other patients in need. Within a few years under Dr. Lau’s leadership, Spirovant gained the prestigious scientific support of the Cystic Fibrosis Foundation and was acquired twice (in one year), most recently by Sumitomo Pharma. As CEO of Spirovant, she has been selected to receive the Ernst & Young Entrepreneur of the Year 2020 Award in Greater Philadelphia and was named a Woman of Distinction by the Philadelphia Business Journal.

Previously, Dr. Lau co-founded and served as Managing Partner of Militia Hill Ventures, focused on building and growing high quality life sciences companies. Dr. Lau also has served as President and CEO of Azelon Pharmaceuticals, a venture-backed clinical stage company; President and CEO of Locus Pharmaceuticals, a computational chemistry discovery company; and in various leadership roles at Merck, including roles in R&D drug development and business development.

In addition, Dr. Lau is an adjunct instructor at the University of Pennsylvania. She also serves on several boards including the University of Pennsylvania’s School of Social Policy and Practice and the Roy & Diana Vagelos Program in Life Sciences Management, and she co-founded the nonprofit PhillyBio, an organization focused on fostering relationships across Philadelphia-based biopharma. 

Dr. Lau earned her MBA from the Wharton School of Business at the University of Pennsylvania, her PhD in Neuroscience from the University of Cincinnati College of Medicine, and her BS in Bioengineering from the University of Pennsylvania.

Chief Medical Advisor

Eric Yuen, MD

Chief Medical Advisor

Eric Yuen, MD

Eric Yuen is the Chief Medical Advisor to Spirovant and a clinical development physician with over 20 years of experience in academia and industry.  During his career, Dr. Yuen has developed numerous biologics and small molecule therapeutics for a variety of diseases, including rare genetic diseases and neurology, psychiatry, pain and oncology disorders.  Dr. Yuen has led departments responsible for Phase I-IV development and submissions of numerous INDs, CTAs, NDAs and MAAs.

Dr. Yuen was the Director of Clinical Research at Merck & Co., working on CNS and pain indications, and later Vice President of Clinical Development at Johnson & Johnson.  While at Johnson & Johnson, Dr. Yuen served as the therapeutic area head for CNS and the head of clinical development at a monoclonal antibodies and vaccines joint venture between Johnson & Johnson and Elan. He later served as CMO of Ultragenyx, a start-up company focused on rare genetic diseases, as VP Clinical Development at BioClin Therapeutics, a start-up focused on the rare genetic disorder achondroplasia (dwarfism) and bladder cancer, and was CMO and co-founder of Talee Bio.

Earlier in his career, Dr. Yuen was an assistant professor of neurology at the University of Washington where he conducted clinical research in rare disorders such as ALS and muscular dystrophies. He received his BA from Stanford University, MD from the University of Chicago, Pritzker School of Medicine, and completed his neurology residency at UCSF and his post-doctoral fellowship at UCSF studying neurotrophic factor signaling.

Chief Scientific Officer

Roland Kolbeck, PhD

Chief Scientific Officer

Roland Kolbeck, PhD

Dr. Roland Kolbeck is Chief Scientific Officer of Spirovant and is responsible for leading the company’s research efforts and for identifying future gene therapy assets to build the pipeline. He delivers more than 20 years of research and executive leadership experience, specializing in respiratory and autoimmune sciences. Previously Dr. Kolbeck held executive roles of increasing responsibility and leadership at MedImmune, AstraZeneca’s global biologics organization. Most recently, he served as Vice President, Head of Respiratory, Inflammation and Autoimmune research (RIA), RIA Research Committee Chair and a member of the MedImmune Research Leadership Team as well as the Early Stage Portfolio Committee. During his tenure there, he set the scientific vision for more than 80 scientists; led the advancement of eight novel candidates into the clinic, including FASENRA®, AstraZeneca’s first biological for the treatment of severe eosinophilic asthma; and contributed to the spinout of six pre/clinical-stage autoimmune assets. Prior to that, he held senior scientific roles at Peptimmune and Millennium Pharmaceuticals.

Dr. Kolbeck conducted his postdoctoral research in the Department of Neurobiochemistry at the Max-Planck Institute for Neurobiology, Munich. He earned a PhD from the University of Regensburg and Max-Planck Institute of Neurobiology, Munich. Dr. Kolbeck has (co)-authored more than 100 publications and is co-inventor on 6 pending or granted patents.

Chief Technology Officer

Eric Pastor

Chief Technology Officer

Eric Pastor

Eric Pastor, Chief Technology Officer

Eric Pastor brings more than 20 years of viral vector CMC and technical operations experience and is responsible for expanding Spirovant’s technology development and manufacturing capabilities. He was most recently Vice President, CMC Operations, for Vedere Bio in Cambridge, MA where he was responsible for building out a product development team and overseeing the overall CMC strategy. Previously, Eric served in a number of scientific positions at Sanofi in Framingham, MA, mostly recently as Head of Gene Therapy Process Development and CMC representative on the Sanofi Gene Therapy Global Project Team. Prior to Sanofi, Eric led the gene therapy analytical group at Targeted Genetics Corporation in Seattle, Washington. He earned a Bachelor of Science degree at the University of Northern British Columbia.

Chief Development Officer

Jessica Lee

Chief Development Officer

Jessica Lee

Jessica has over 25 years of drug development experience, including early discovery and Phase 1-3 clinical trial experience across a variety of therapeutic areas. Throughout her career, Jessica has had increasing levels of responsibility and currently serves as Chief Development Officer at Spirovant Sciences, Inc, where she has responsibilities for the clinical development and regulatory strategy of Spirovant’s Cystic Fibrosis and respiratory disease product portfolio. She has led groups responsible for Clinical Operations, Data Management, Epidemiology, Pharmacovigilance, and Compliance and was most recently SVP Clinical Science and Operations at Inovio Pharmaceuticals in Blue Bell, PA. Jessica has authored and submitted numerous INDs, CTAs, BLAs, and NDAs and has managed complex drug/biologic/device programs in collaboration with industry, government, NGOs, and academic partners.

Jessica received her MPH from Drexel University Dornsife School of Public Health and her MS from Temple University School of Pharmacy.

Chief Financial Officer

David Whitwell, MBA

Chief Financial Officer

David Whitwell, MBA

David Whitwell is an entrepreneurially focused financial executive with thirty years of broad financial, accounting and management experience. He has been acting CFO for Spirovant since 2019. In 2021 David started Whitwell CFO LLC to provide CFO services to emerging biotech, healthcare, and technology companies. Prior to starting his own company, David was a partner for 13 years with B2B CFO® Partners LLC where he provided CFO advisory services to companies including Circa HeathCare, Versify Solutions, Locus Pharmaceutical, and Onpath Technologies. He was CFO for two small public companies, IWT Tesoro and Clean Diesel Technologies Inc as well as Divisional CFO for a large multi-billion entity, Primedia, in NYC. He was Manager of Finance with Merck (Schering-Plough) and started his career in public accounting with the Philadelphia office of Ernst & Young.


David has a B.S. in Accounting from The Pennsylvania State University and an MBA from Lehigh University. He is a CPA (inactive) and was a certified management accountant.

NEWSROOM

Spirovant Sciences, a biotechnology company located in Philadelphia, is a leader in the development of gene therapies for cystic fibrosis (CF) and other lung diseases.